.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The 2025 Bridging the Gaps Consensus Conference recently provided crucial updates on multiple myeloma management. A panel of 16 experts reviewed the latest clinical data to address existing gaps and therapeutic sequencing. Consequently, they developed 11 consensus recommendations spanning from smoldering disease to relapsed settings. Furthermore, these guidelines emphasize the integration of quadruplet induction and the strategic use of cellular therapies to improve outcomes.
The experts reached a strong consensus regarding the use of quadruplet regimens in the frontline setting. Specifically, adding a monoclonal antibody to the standard triplet backbone is now recommended for most patients. Additionally, the panel discussed the role of individualized maintenance therapy based on patient risk factors. However, they noted that the optimal duration of maintenance remains an area for further investigation. Moreover, early referral for CAR-T therapy is critical for patients experiencing early relapse. Therefore, hematologists should coordinate with transplant centers much sooner in the disease course.
Notably, the consensus highlights the growing importance of minimal residual disease (MRD) monitoring. Thus, MRD status may eventually guide treatment intensification or de-escalation decisions. Ultimately, these recommendations provide a practical roadmap for clinicians navigating the complex myeloma landscape. By standardizing care across different disease stages, the panel aims to improve long-term patient survival. Finally, ongoing research remains essential to refine these expert-derived pathways and address remaining controversies.
Quadruplet induction regimens, such as those combining a CD38-targeted antibody with a proteasome inhibitor and an immunomodulatory drug, offer higher rates of deep and durable responses compared to standard triplets.
Early referral ensures that patients with relapsed or refractory disease can access specialized cellular therapies before their clinical condition deteriorates, maximizing the potential for significant therapeutic benefit.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.
References
Chari A et al. Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference. Am J Hematol. 2026 Apr 21. doi: 10.1002/ajh.70339. PMID: 42014940.
Chari A, Bal S, Ailawadhi S, et al. Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2025 Sep;25(9):635-645. doi: 10.1016/j.clml.2025.03.008.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The 2025 Bridging the Gaps Conference offers 11 recommendations for multiple myeloma, focusing on quadruplet induction, maintenance, and CAR-T therapy....
4 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
